<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="180">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 22, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02274155</url>
  </required_header>
  <id_info>
    <org_study_id>14-042A</org_study_id>
    <nct_id>NCT02274155</nct_id>
  </id_info>
  <brief_title>Anti-OX40 Antibody in Head and Neck Cancer Patients</brief_title>
  <official_title>Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Providence Health &amp; Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Providence Health &amp; Services</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given
      prior to surgery in patients with advanced head and neck squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase Ib clinical trial uses MEDI6469 at various dose intervals prior to definitive
      surgical resection of patients with stage III and IV Oral Head and Neck Squamous Cell
      Carcinoma (OHNSCC) with the primary objective of determining the safety and feasibility of
      preoperative MEDI6469 administration. In addition, tumor tissue and peripheral blood will be
      obtained for exploratory immunologic end points including measurements of tumor infiltrating
      immune cell populations based on flow cytometry and immunohistochemistry as well as
      circulating immunological parameters that may correlate with changes induced by MEDI6469
      administration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and feasibility of definitive surgical resection for locoregionally advanced OHNSCC following MEDI6469 administration</measure>
    <time_frame>55 Days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be seen in clinic 7 times over 55 days to identify any possible side effects or complications thought to be related to the study drug to help identify the optimal treatment schedule.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunologic phenotypes of lymphocyte subsets</measure>
    <time_frame>55 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>An uninvolved tumor-draining lymph node, primary tumor, and metastatic lymph nodes will be obtained during surgery, and peripheral blood will be collected 7 times over 55 days to identify the composition and immunologic phenotypes of lymphocyte subsets. This will also be compared to historical controls.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical Outcome of Imaging</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical surveillance for recurrence as per PET +/- CT within 6 months of completion of treatment exam. Clinical outcomes will be compared to historical controls.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-OX40 antibody administration 3 weeks prior to surgical resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-OX40 antibody administration 2 weeks prior to surgical resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-OX40 antibody administration 1 week prior to surgical resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-OX40 antibody administration</intervention_name>
    <description>Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>MEDI6469</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical Resection</intervention_name>
    <description>Surgical Resection of Tumor</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with treatment naive, resectable, stage III or IV squamous cell carcinoma of
             the oral cavity, oropharynx, hypopharynx or larynx who are candidates for definitive
             surgical resection followed by standard risk adapted adjuvant therapy.

          -  Histologic or cytologic diagnosis of a primary OHNSCC with no radiological evidence
             of metastatic disease is acceptable. Patients with bone or cartilage invasion and any
             T or N stage are acceptable.

          -  Patients with oral cavity primaries will be managed using conventional transoral or
             transcervical techniques; oropharynx or hypopharynx tumor will be managed with
             transoral robotic surgery; and larynx tumors (T3/T4 with thyroid cartilage invasion)
             will be managed by either total laryngectomy or larynx preservation surgery.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

          -  Laboratory values (performed within 28 days prior to enrollment) within protocol
             defined range

          -  Ability to give informed consent and comply with the protocol. Patients with a
             history of psychiatric illness must be judged able to understand the investigational
             nature of the study and the risks associated with the therapy.

          -  No active gastrointestinal bleeding.

          -  Anticipated lifespan greater than 12 weeks.

        Exclusion Criteria:

          -  Locoregionally unresectable or Metastatic disease (stage IVB)

          -  Active infection.

          -  Active autoimmune disease including patients with Inflammatory Bowel Disease as
             determined by an autoimmune questionnaire.

          -  Previous treatment with mouse monoclonal antibodies

          -  Need for chronic maintenance oral steroids &gt; 5mg prednisone daily equivalent.

          -  Any medical or psychiatric condition that in the opinion of the investigator would
             preclude compliance with study procedures.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard B. Bell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brenda Fisher, RN</last_name>
    <phone>(503) 215-2613</phone>
    <email>Brenda.Fisher@Providence.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Portland Providence Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Fisher, RN</last_name>
      <phone>503-215-2613</phone>
      <email>Brenda.Fisher@providence.org</email>
    </contact>
    <investigator>
      <last_name>Brendan Curti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Crocenzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Sanborn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Walter J. Urba, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alison Conlin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Godwin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rom Leidner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rui Li, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard B. Bell, MD, DDS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tuan Bui, MD, DDS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Dierks, MD, DMD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allen Cheng, MD, DMD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://oregon.providence.org/our-services/p/providence-cancer-center/</url>
    <description>Providence Cancer Center</description>
  </link>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 29, 2015</lastchanged_date>
  <firstreceived_date>October 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>anti-OX40 antibody</keyword>
  <keyword>MEDI6469</keyword>
  <keyword>Immunotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
